| Lipids Management |
0 |
0.91 |
| Type 2 Diabetes Mellitus |
0 |
0.68 |
| Statins |
0 |
0.67 |
| GLP-1 Receptor Agonist |
0 |
0.58 |
| Cardiovascular Risk Management |
0 |
0.49 |
| Receptors |
0 |
0.37 |
| Angiotensin II Receptor Blockade |
0 |
0.31 |
| Coronary Artery Disease (CAD) |
0 |
0.31 |
| Blood |
0 |
0.3 |
| Hypertension |
0 |
0.27 |
| ACE Inhibitor |
0 |
0.22 |
| Cardiovascular disease |
0 |
0.22 |
| SGLT2 Inhibitor |
0 |
0.22 |
| Clinical Guidelines |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Face |
0 |
0.07 |
| Hyperglycemia |
0 |
0.07 |
| Muscle |
0 |
0.07 |
| Primary Care |
0 |
0.07 |
| Travel Medicine |
0 |
0.07 |